Trial Profile
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study With an Open Label Extension to Evaluate the Efficacy and Safety of KHK4827 in Subjects With Moderate to Severe Plaque Psoriasis
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Brodalumab (Primary)
- Indications Plaque psoriasis
- Focus Registrational; Therapeutic Use
- Sponsors Kyowa Hakko Kirin Korea
- 01 Jun 2021 Primary endpoint (Static physicians global assessment (sPGA) of 0 (clear) or 1 (almost clear)) has been met, as per results published in the Journal of Dermatology.
- 01 Jun 2021 Primary endpoint (Psoriasis area and severity index (PASI) 75 response) has been met, as per results published in the Journal of Dermatology.
- 01 Jun 2021 Results assessing efficacy, safety and pharmacokinetics of brodalumab in patients with moderate to severe plaque psoriasis, published in the Journal of Dermatology.